Vaccine (DNA plasmid) · Immune activation, directed at Ebola virus glycoprotein · developed by INOVIO PHARMACEUTICALS
INO-4201 is a plasmid DNA vaccine administered intradermally with electroporation. It is studied in Ebola virus disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04906629 | Phase 1 | Ebola Virus Disease | Completed | INO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Ebola Virus Disease
Updated Oct 3, 2026. Something wrong or missing? Report it on the INO page.
See INO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INO catalysts and pipeline →